Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
出版年份 2023 全文链接
标题
Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
作者
关键词
-
出版物
Cancer Medicine
Volume 12, Issue 11, Pages 12299-12315
出版商
Wiley
发表日期
2023-05-07
DOI
10.1002/cam4.5927
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis
- (2023) Raymond Ngai Chiu Chan et al. European Journal of Internal Medicine
- Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study
- (2022) Oscar Hou In Chou et al. Clinical Research in Cardiology
- Association Between DPP-4 Inhibitors and Events of Colorectal and Liver Cancers in Patients With Diabetes Receiving Second-Line Agents: A Nested Case-Control Study
- (2022) Chu-Lin Chou et al. Frontiers in Oncology
- Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
- (2022) Mu-Chi Chung et al. Scientific Reports
- Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
- (2022) Kevin Yau et al. Kidney International Reports
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
- (2021) Mariusz Dąbrowski INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
- (2021) Lesley A. Inker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin suppresses breast cancer growth via inhibition of cyclooxygenase‑2
- (2021) Bin Shi et al. Oncology Letters
- Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
- (2021) Lui Ng et al. Cancers
- SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
- (2021) Nanjing Shi et al. Frontiers in Public Health
- Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes
- (2021) Philip C M Au et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials
- (2021) Rosaria Benedetti et al. PHARMACOLOGICAL RESEARCH
- Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study
- (2021) György Rokszin et al. Frontiers in Oncology
- Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
- (2020) Ilaria Dicembrini et al. ACTA DIABETOLOGICA
- Sodium glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
- (2020) Rachel J. Perry et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
- (2020) Jun Zhou et al. BIOMEDICINE & PHARMACOTHERAPY
- Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
- (2020) Jiandong Zhou et al. GUT
- Sodium-glucose cotransporters: new targets of cancer therapy?
- (2019) Ivana Vrhovac Madunić et al. Arhiv za Higijenu Rada i Toksikologiju-Archives of Industrial Hygiene and Toxicology
- Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis
- (2019) Long Yao et al. DISEASE MARKERS
- The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
- (2019) Teruo Jojima et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Does long-term use of antidiabetic drugs changes cancer risk?
- (2019) Yi-Chun Liu et al. MEDICINE
- Type 2 Diabetes and Risk of Incident Cancer in China: A Prospective Study Among 0.5 Million Chinese Adults
- (2018) Xiong-Fei Pan et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
- (2018) Kumiko Shiba et al. Scientific Reports
- Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts
- (2018) Yanan Ma et al. BRITISH JOURNAL OF CANCER
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
- (2017) Kosuke Kaji et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
- (2017) Haoyu Kuang et al. MEDICAL SCIENCE MONITOR
- Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- (2017) Ming Zhao et al. Scientific Reports
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
- (2016) Linda A. Villani et al. Molecular Metabolism
- Effect of dapagliflozin on colon cancer cell [Rapid Communication]
- (2015) Tsugumichi Saito et al. ENDOCRINE JOURNAL
- An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
- (2015) Chin-Hsiao Tseng et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
- (2014) C. Bosetti et al. ANNALS OF ONCOLOGY
- Repositioning metformin for cancer prevention and treatment
- (2013) Brendan J. Quinn et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search